Uni-Bio Science Group

Uni-Bio Science Group OCF Margin

The Operating Cash Flow Margin of Uni-Bio Science Group (690.HK) as of Oct 15, 2026 is 12.06 %. In the previous year, Operating Cash Flow Margin was 20.39 % — a change of -40.85% (lower).

OCF Margin

12.06 %

YoY

-40.85%

Last updated:

Operating Cash Flow Margin of Uni-Bio Science Group is 2024 12.06 % . Operating Cash Flow Margin of Uni-Bio Science Group was 2023 20.39 % . It decreases by -40.85% lower compared to the previous year.

The Uni-Bio Science Group OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2017
-43.84 HKD
Jan 1, 2018
-65.80 HKD
Jan 1, 2019
-14.68 HKD
Jan 1, 2020
-7.41 HKD
Jan 1, 2021
3.41 HKD
Jan 1, 2022
11.05 HKD
Jan 1, 2023
20.39 HKD
Jan 1, 2024
12.06 HKD
The Uni-Bio Science Group OCF Margin history
YEAROCF MarginYoY
12.06 %-40.85%
20.39 %+84.53%
11.05 %+224.33%
3.41 %-145.97%
-7.41 %-49.51%
-14.68 %-77.69%
-65.80 %+50.08%
-43.84 %+171.10%
-16.17 %+58.40%
-10.21 %-84.32%
-65.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd, listed on the Hong Kong Stock Exchange under ticker 690.HK with ISIN KYG9198H1406, operates in the Health Care sector within the Biotechnology industry. The company, which completed its IPO on November 12, 2001, employs 340 full-time staff. Uni-Bio Science Group functions through four business segments. The In-house Chemical Pharmaceutical Products segment focuses on manufacturing and selling proprietary chemical pharmaceutical products, including the product named Pinapu. The In-house Biological Pharmaceutical Products segment handles the production and distribution of biological pharmaceutical products such as GeneTime and GeneSoft. The In-house Biological Pipeline segment is dedicated to advancing the industrialization of its biological pipeline, featuring products like Uni-E4 and Uni-PTH. The Third-party Pharmaceutical Products segment manages the sales of pharmaceutical products from external suppliers. The company's headquarters location is not publicly specified, and its official website is www.uni-bioscience.com. Uni-Bio Science Group's business model integrates in-house development with third-party product distribution, targeting both chemical and biological pharmaceutical markets. The company's operational structure reflects a diversified approach to pharmaceutical research, development, and commercialization, though specific details about its research pipeline, market reach, or financial performance are not provided in the available information. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uni-Bio Science Group stock

Operating Cash Flow Margin of Uni-Bio Science Group is 12.06 % in 2024.

Operating Cash Flow Margin of Uni-Bio Science Group changed from 20.39 % to 12.06 %, representing a -40.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Uni-Bio Science Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group